Journal of Clinical Case Reports

Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco

Publications

• Case Report   
  Pathological Complete Response with CDK 4/6 Inhibitors in HR+/HER2- Locally Breast Cancer: Case of a Benign Bone Lesion Misidentified as Metastatic
  Author(s): Bekkouche Soukaina*, Najem Salma, Harrak Soukaina, Abdi Chaimae, M’rabti Hind, Boutayeb Saber, El Guisssassi Ibrahim and Errihani Hassan
  
  Locally advanced breast cancer presents significant challenges to the multidisciplinary team, particularly in cases involving hormone receptor (HR)-positive, HER2-negative tumors, which typically show lower rates of pathological complete response to chemotherapy. Cyclin-Dependent Kinase (CDK) 4/6 inhibitors are the cornerstone of treatment in metastatic Hormone Receptor (HR)-positive, HER2-negative breast cancer and have more recently been considered in the adjuvant setting. However, their effectiveness in the neoadjuvant setting remains uncertain. We report the case of a 55-year-old postmenopausal woman initially diagnosed with metastatic HR+/HER2- breast cancer due to a unique L5 bone lesion. Systemic treatment was initiated with an Aromatase Inhibitor (AI) and a CDK4/6 inhibitor. After six months of treatment, imaging reevaluation confirmed that the L5 l.. Read More»
  DOI: 10.37421/2165-7920.2024.14.1621

  Abstract HTML PDF